About 30% of all human cancers bear activating rat sarcoma (RAS) mutations; in particular, Kirsten rat sarcoma (KRAS) mutations are considerably more frequent than Harvey rat sarcoma virus oncogene (HRAS) and Neuroblastoma RAS Viral Oncogene Homolog (NRAS) mutations. Here, KRAS is linked to cancer.